Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids

Cancer Cell International

Volumn 5, Issue , 2005, Pages

  Ponce de León, Valeria ^a   Barrera Rodríguez, Raúl ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Multicellular drug resistance; Multicellular spheroids; NSCLC; P Glycoprotein

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLOSPORIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123;

ARTICLE; CANCER GROWTH; CELL CLONING; CELL MUTANT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG RETENTION; HUMAN; HUMAN CELL; LUNG CANCER; MONOLAYER CULTURE; MULTICELLULAR SPHEROID; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 26844497219     PISSN: 14752867     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-5-20     Document Type: Article

References (57)

1. Hrycyna C: Molecular genetic analysis and biochemical characterization of mammalian P-glycoprotein involved in multidrug resistance. Cell Dev Biol 2001, 12:247-256.
2. Sauna ZE, Smith MM, Müller M, Kerr KM, Ambudkar SV: The Mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenergetics Biomembranes 2001, 33:481-491.
3. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2:48-58.
4. Takeshita H, Kusuzaki K, Ashihara T, Gebhardt MC, Mankin HJ, Hirasawa Y: Actin organization associated with the expression of multidrug-resistant phenotype in osteosarcoma cells and the effect of actin depolymerization on drug resistance. Cancer Lett 1998, 126:75-81.
5. Luciani F, Molinari A, Lozupone F, Calcabrini A, Lugini L, Strigaro A, Puddu P, Arancia G, Cianfriglia M, Fais S: P-Glycoprotein-actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin. Blood 2002, 99:641-648.
6. Callaghan R, van Gorkom LC, Epand RM: A comparison of membrane properties and composition between cell lines selected and transfected for multi-drug resistance. Br J Cancer 1992, 66:781-786.
7. Le Moyec L, Tatoud R, Degeorges A, Calabresse C, Bauza G, Eugene M, Calvo F: Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line. Cancer Res 1996, 56:3461-3467.
8. Sutherland RM, Eddy HA, Bareham B, Reich K, Vanantwerp D: Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys 1979, 5:1225-1230.
9. Mueller-Klieser W: Three-dimensional cell cultures: from molecular mechanism to clinical applications. Am J Physiol 1997, 273:C1109-1123.
10. Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS: Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA 1993, 90:3294-3298.
11. Kolchinsky A, Roninson IB: Drug resistance conferred by MDR1 expression in spheroids formed by glioblastoma cell lines. Anticancer Res 1997, 17:3321-3327.
12. Desoize B, Gimonet D, Jardiller JC: Cell culture as spheroids: an approach to multicellular resistance. Anticancer Res 1998, 18:4147-4158.
13. Kerbel RS, Rak J, Kobayashi H, Man MS, St Croix B, Granham CH: Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. Cold Spring Harb Symp Quant Biol 1994, 59:661-672.
14. Yuhas JM, Li AP, Martinez AO, Landman AJ: A simplified method for production and growth of multicellular tumor spheroids. Cancer Res 1977, 37:3639-3643.
15. Beketic-Oreskovic L, Durán GE, Chen G, Dumontet C, Sikic BI: Decrease mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the Cyclosporin PCS 833. J Natl Cancer Inst 1995, 87:1593-1602.
16. Cole SP: Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol 1986, 17:259-263.
17. Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Takeuchi T, Kase S, Kadaira S, Ishibiki K, Kitajima M, Hoffman RM: High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 1992, 51:489-498.
18. Wartenberg M, Frey C, Diedershagen H, Ritgen J, Hescheler J, Sauer H: Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids. Int J Cancer 1998, 75:855-863.
19. Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Functional expression of human P-glycoprotein from plasmids using vaccinia virus-bacteriophage T7 RNA polymerase system. Methods Enzymol 1998, 292:456-473.
20. Moriyama Y, Manabe T, Yoshimori T, Tashiro Y, Futai M: ATP-dependent uptake of anti-neoplastic agents by acidic organelles. J Biochem (Tokyo) 1994, 115:213-218.
21. Schindler M, Grabski S, Hoff E, Simon SM: Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in Adriamycin resistant cells (MCF-7adr). Biochemistry 1996, 35:2811-2817.
22. Nederman T, Norling B, Glimelius B, Carlsson J, Brunk U: Demonstration of an extracellular matrix in multicellular tumor spheroids. Cancer Res 1984, 44:3090-3097.
23. Bichat F, Mouawad R, Solis-Recendez G, Khayat D, Bastian G: Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line. Anticancer Res 1997, 17:3393-3402.
24. dit Faute MA, Laurent L, Ploton D, Poupon MF, Jardillier JC, Bobichon H: Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis 2002, 9:161-168.
25. Jakubowicz-Gil J, Paduch R, Gawron A, Kandefer-Szerszen M: The effect of heat shock, cisplatin, etoposide and quercetin on Hsp27 expression in human normal and tumour cells. Folia Histochem Cytobiol 2002, 40:31-35.
26. 1H MRS studies of signals from mobile lipids and from lipid metabolites: comparison of the behavior in cultured tumor cells and in spheroids. NMR Biomed 2004, 17:76-91.
27. Hazlehurst LA, Dalton WS: Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoitec malignances. Cancer Metastasis Rev 2001, 20:43-50.
28. Wartenberg M, Ling FC, Muschen M, Klein F, Acker H, Gassmann M, Petrat K, Putz V, Hescheler J, Sauer H: Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 2003, 17:503-505.
29. Pedro D, Beltran PJ, Wang YF, Bucana CD, Yoon SS, Deguzman ACP, Fidler IJ: Cell density-dependent regulation of mdr-1 gene expression in murine colon cancer cells. Int J Oncol 1996, 9:865-878.
30. Tunggal JK, Melo T, Ballinger JR, Tannock IF: The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers. Int J Cancer 2000, 86:101-107.
31. Tritton TR: Cell surface actions of adriamycin. Pharmacol Ther 1991, 49:293-309.
32. Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert JM: Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochim Biophys Acta 1980, 597:1-14.
33. Martin C, Walker J, Rothnie A, Callaghan R: The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models. Br J Cancer 2003, 89:1581-1589.
34. Alemán C, Annereau JP, Liang XJ, Cardarelli CO, Taylor B, Yin JJ, Aszalos A, Gottesman MM: P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res 2003, 63:3084-3091.
35. Ferté J: Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem 2000, 267:277-294.
36. Eytan GD, Regev R, Oren G, Assaraf YG: The role of passive transbilayer drug movement in multidrug resistance and its modulation. J Biol Chem 1996, 271:12897-12902.
37. Ehrlich PH, Moustafa ZA, Archinal-Mattheis AE, Newman MJ, Bair KW, Cohen D: The reversal of multidrug resistance in multicellular tumor spheroids by SDZ PSC 833. Anticancer Res 1997, 17:129-133.
38. Anderson M, Warr JR: Expression of verapamil hypersensitivity in multidrug-resistant cells grown as multicellular spheroids. Cancer Chemother Pharmacol 1990, 26:151-154.
39. Sakata K, Kwok TT, Gordon GR, Walch NS, Sutherland RM: Resistance to verapamil sensitization of multidrug-resistant cells grown as multicellular spheroids. Int J Cancer 1994, 59:282-286.
40. Tunggal JK, Cowan DS, Shaikh H, Tannock IF: Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of hemotherapy for solid tumors. Clin Cancer Res 1999, 5:1583-1586.
41. He L, Liu GQ: Interaction of multidrug resistance reversal agents with P-glycoprotein ATPase activity on blood-brain barrier. Acta Pharmacol Sin 2002, 23:423-429.
42. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R: Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000, 58:624-632.
43. Hicks KO, Ohms SJ, van Zijl PL, Denny WA, Hunter PJ, Wilson WR: An experimental and mathematical model for the extravascular transport of DNA intercalator in tumours. Br J Cancer 1997, 76:894-903.
44. Cowan DSM, Hicks KO, Wilson WR: Multicellular membranes as in vitro model for extravascular diffusion in tumours. Br J Cancer 1996, 74(Suppl XXVII):528s-531s.
45. Bertram J, Palfner K, Hiddemann W, Kneba M: Increase of P-glycoprotein-mediated drug resistance by hsp 90 beta. Anticancer Drugs 1996, 7:838-845.
46. Millward MJ, Cantwell BM, Munro NC, Robinson A, Corris PA, Harris AL: Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer 1993, 67:1031-1035.
47. Biswas EE: Nucleotide binding domain 1 of the human retinal ABC transporter functions as a general ribonucleotidase. Biochemistry 2001, 40:8181-8187.
48. Gottesman MM: Mechanisms of cancer resistance. Ann Rev Medicine 2002, 53:615-657.
49. Doyle LA, Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP ABCG2. Oncogene 2003, 22:7340-7358.
50. Honjo Y, Hrycyna CA, Yan Q-W, Medina-Perez WY, Robery RW, van de Laar A, Litman T, Dean M, Bates SE: Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001, 61:6635-6639.
51. Oloumi A, MacPhail SH, Johnston PJ, Banath JP, Olive PL: Changes in subcellular distribution of topoisomerase II alpha correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res 2000, 60:5747-5753.
52. Luo C, Johnston PJ, MacPhail SH, Banath JP, Oloumi A, Olive PL: Cell fusion studies to examine the mechanism for etoposide resistance in Chinese hamster V79 spheroids. Exp Cell Res 1998, 243:282-289.
53. Zhao R, Goldman ID: Resistance to antifolates. Oncogene 2003, 22:7340-7358.
54. Scagliotti GV, Novello S, Salvaggi G: Multidrug resistance in non-small-cell lung cancer. Ann Oncol 1999, 10:S83-86.
55. Yeh JJ, Hsu WH, Wang JJ, Ho ST, Kao A: Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration 2003, 70:32-35.
56. Volm M, Mattern J, Samsel B: Overexpression of P-gp and glutathione S-transferase-π in resistant non-small cell lung carcinomas of smokers. Br J Cancer 1991, 64:700-704.
57. Oka M, Fukuda M, Sakamoto A, Takatani H, Fukuda M, Soda H, Kohno S: The clinical role of MDR1 gene expression in human lung cancer. Anticancer Res 1997, 17:721-724.